Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron set to commence Clostridium Difficile Infection study in Israel

The company’s IMM-529 is a naturally produced biological antibody product
Immuron set to commence Clostridium Difficile Infection study in Israel
The primary objective of the study is to assess IMM-529's safety and tolerability

Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

CDI is a condition, acute especially in hospitals and in long-term in-patient care facilities due to bacterial toxin causing inflammation of the colon resulting in diarrhoea and in severe cases, death.

This is Immuron's first human clinical study using its IMM-529 product, following the results reported from a series of pre-clinical efficacy studies completed at Monash University.

READ: Immuron targets cash injection

IMM-529 is a naturally produced biological antibody product intended to prevent and treat CDI and designed to spare the gut microbiome from the effects of classic antibiotic treatments.

The new study is to be conducted at the Hadassah Medical Center in Jerusalem. Approval has been granted by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health.

Immuron's clinical trial is designed to study a total of 60 patients diagnosed with CDI and have received standard of care antibiotic treatment.

Patients will be enrolled within three weeks of their diagnosis and will be randomised into either IMM-529 three times daily, or placebo, for 28 days.

The primary objective of the study is to assess IMM-529's safety and tolerability.

Immuron’s secondary endpoints are to evaluate the preliminary efficacy of IMM-529 as evaluated by the duration and severity of the symptoms and rate of disease recurrence.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use